<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en"><id>http://publicationslist.org/data/noemi.orzan/atom.xml</id><title>Francesca Orzan's Publications List</title>
<link rel="self" type="application/atom+xml" href="http://publicationslist.org/data/noemi.orzan/atom.xml"/><link rel="alternate" type="text/html" href="http://publicationslist.org/noemi.orzan"/><author><name>Francesca Orzan</name><uri>http://publicationslist.org/noemi.orzan</uri></author><icon>$basepathfavicon.ico</icon><subtitle>Recent additions to Francesca Orzan's PublicationsList.org page</subtitle><logo>http://publicationslist.org/publications.png</logo><updated>2010-06-09T07:23:06Z</updated>

<entry>
<id>http://publicationslist.org/noemi.orzan/refid8</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid8'/>
<title type='html'>Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.</title>
<summary type='html'>Pilot data showed that adding intratumoral (IT) injection of dendritic cells (DCs) prolongs survival of patients affected by glioblastoma multiforme (GBM) treated by subcutaneous (SC) delivery of DCs. Using a murine model resembling GBM, we investigated the immunological mechanisms underlying this effect. C57BL6/N mice received brain injections of GL261 glioma cells. Seven days later, mice were tr...&lt;br/&gt;&lt;br/&gt;Serena Pellegatta, Pietro Luigi Poliani, Elena Stucchi, Daniela Corno, Chiara Agnese Colombo, Francesca Orzan, Maria Ravanini, Gaetano Finocchiaro (2010)  &lt;i&gt;Neuro Oncol&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 12: 4 377-388&lt;br/&gt;</summary>
</entry>
<entry>
<id>http://publicationslist.org/noemi.orzan/refid3</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid3'/>
<title type='html'>Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.</title>
<summary type='html'>Chordomas are rare embryogenetic tumors, arising from remnants of the notochord, characterized by local invasiveness and variable tendency for recurrence. No molecular markers are currently used in a clinical setting to distinguish chordomas with an indolent or an aggressive pattern. Among the genetic lesions observed in this tumor, one of the most commonly detected is 1p loss. In a previous study...&lt;br/&gt;&lt;br/&gt;Mauro Longoni, Francesca Orzan, Michela Stroppi, Nicola Boari, Pietro Mortini, Paola Riva (2008)  &lt;i&gt;Neuro Oncol&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 10: 1 52-60&lt;br/&gt;</summary>
</entry>
<entry>
<id>http://publicationslist.org/noemi.orzan/refid2</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid2'/>
<title type='html'>Breakpoint characterization of a novel NF1 multiexonic deletion: a case showing expression of the mutated allele.</title>
<summary type='html'>Neurofibromatosis type 1 (NF1) is a common genetic disease caused by haploinsufficiency of the NF1 tumor-suppressor gene. Different pathogenetic mechanisms have been identified, with the majority (95%) causing intragenic lesions. Single or multiexon NF1 copy number changes occur in about 2% of patients, but little is known about the molecular mechanisms behind these intragenic deletions. We report...&lt;br/&gt;&lt;br/&gt;Francesca Orzan, Michela Stroppi, Marco Venturin, M Carmen Valero, Concepcion Hernández, Paola Riva (2008)  &lt;i&gt;Neurogenetics&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 9: 2 95-100&lt;br/&gt;</summary>
</entry>
<entry>
<id>http://publicationslist.org/noemi.orzan/refid4</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid4'/>
<title type='html'>Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.</title>
<summary type='html'>Chordomas are rare neoplasms arising along the axial skeleton. Up to now, the most suitable therapeutic approach is based on a combination of surgical excision and radiotherapy. Chemotherapy in not applied due to its reported low efficacy. Recently, evidence on the efficacy of Imatinib mesylate in two patients has been reported. We analyzed 14 chordoma samples for the expression of the Imatinib me...&lt;br/&gt;&lt;br/&gt;Francesca Orzan, Maria Rosa Terreni, Mauro Longoni, Nicola Boari, Pietro Mortini, Claudio Doglioni, Paola Riva (2007)  &lt;i&gt;Oncol Rep&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 18: 1 249-252&lt;br/&gt;</summary>
</entry>
<entry>
<id>http://publicationslist.org/noemi.orzan/refid5</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid5'/>
<title type='html'>Uncommon Alu-mediated NF1 microdeletion with a breakpoint inside the NF1 gene.</title>
<summary type='html'>Neurofibromatosis type 1 (NF1) microdeletion syndrome is caused by haploinsufficiency of the NF1 gene and of gene(s) located in adjacent flanking regions. Most of the NF1 deletions originate by nonallelic homologous recombination between repeated sequences (REP-P and -M) mapped to 17q11.2, while a few uncommon deletions show unusual breakpoints. We characterized an uncommon 1.5-Mb deletion of an N...&lt;br/&gt;&lt;br/&gt;Cristina Gervasini, Marco Venturin, Francesca Orzan, Alessandra Friso, Maurizio Clementi, Romano Tenconi, Lidia Larizza, Paola Riva (2005)  &lt;i&gt;Genomics&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 85: 2 273-279&lt;br/&gt;</summary>
</entry>
<entry>
<id>http://publicationslist.org/noemi.orzan/refid6</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid6'/>
<title type='html'>Evidence for non-homologous end joining and non-allelic homologous recombination in atypical NF1 microdeletions.</title>
<summary type='html'>NF1 microdeletion syndrome is caused by haploinsufficiency of the NF1 gene and of gene(s) located in adjacent flanking regions. Most of the NF1 deletions originate by non-allelic homologous recombination between repeated sequences (REP-P and -M) mapped to 17q11.2, while the remaining deletions show unusual breakpoints. We performed high-resolution FISH analysis of 18 NF1 microdeleted patients with...&lt;br/&gt;&lt;br/&gt;Marco Venturin, Cristina Gervasini, Francesca Orzan, Angela Bentivegna, Lucia Corrado, Patrizia Colapietro, Alessandra Friso, Romano Tenconi, Meena Upadhyaya, Lidia Larizza, Paola Riva (2004)  &lt;i&gt;Hum Genet&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 115: 1 69-80&lt;br/&gt;</summary>
</entry>
<entry>
<id>http://publicationslist.org/noemi.orzan/refid7</id>
<updated>2010-06-09T07:21:28Z</updated>
<link rel='alternate' type='text/html' href='http://publicationslist.org/noemi.orzan#refid7'/>
<title type='html'>Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis.</title>
<summary type='html'>Various cytogenetic and molecular findings indicate 1p36 loss as a consistent change in sporadic and inherited chordoma, a rare embryogenetic neoplasm arising from notochord remnants. We studied 27 sporadic chordomas by means of loss of heterozygosity (LOH) of 31 microsatellites localized to the 1p36.32-36.11 region, and restricted the minimal LOH interval shared by 85% of the tumours to 1p36.13. ...&lt;br/&gt;&lt;br/&gt;Paola Riva, Francesca Crosti, Francesca Orzan, Leda Dalprà, Pietro Mortini, Antonina Parafioriti, Bianca Pollo, Anna Maria Fuhrman Conti, Monica Miozzo, Lidia Larizza (2003)  &lt;i&gt;Int J Cancer&lt;/i&gt; &lt;i&gt;&lt;/i&gt; &lt;i&gt;&lt;/i&gt; 107: 3 493-497&lt;br/&gt;</summary>
</entry>
</feed>
